StemCell Therapy

Cardiff Oncology Inc (CRDF) is around the top of the Biotechnology industry according to InvestorsObserver. CRDF received an overall rating of 89, which means that it scores higher than 89 percent of all stocks. Cardiff Oncology Inc also achieved a score of 99 in the Biotechnology industry, putting it above 99 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cardiff Oncology Inc (CRDF) stock is trading at $13.30 as of 11:34 AM on Thursday, Oct 22, a gain of $1.28, or 10.65% from the previous closing price of $12.02. The stock has traded between $12.50 and $13.41 so far today. Volume today is below average. So far 427,977 shares have traded compared to average volume of 3,743,546 shares.

Click Here to get the full Stock Score Report on Cardiff Oncology Inc (CRDF) Stock.

See the original post here:
Is Cardiff Oncology Inc (CRDF) a Winner in the Biotechnology Industry? - InvestorsObserver

This entry was posted on October 25, 2020 at 5:56 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |